Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
153.95
+1.04 (0.68%)
At close: Feb 5, 2026, 4:00 PM EST
153.85
-0.10 (-0.06%)
Pre-market: Feb 6, 2026, 8:37 AM EST
Novartis AG Revenue
In the year 2025, Novartis AG had annual revenue of $56.67B with 9.57% growth. Novartis AG had revenue of $524.00M in the quarter ending December 31, 2025, with 29.38% growth.
Revenue (ttm)
$56.67B
Revenue Growth
+9.57%
P/S Ratio
5.16
Revenue / Employee
$752,973
Employees
75,267
Market Cap
292.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
| Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
| Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
| Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
| Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
| Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
| Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.13B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
NVS News
- 1 day ago - Novartis: Value Price, Growth Pipeline - Seeking Alpha
- 1 day ago - Novartis AG (NVS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead - Benzinga
- 2 days ago - Novartis Sales Rise Despite Generic Drug Competition in U.S. - WSJ
- 2 days ago - Novartis expects low single-digit decline in 2026 operating profit - Reuters
- 2 days ago - Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025 - GlobeNewsWire
- 17 days ago - Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC - CNBC
- 17 days ago - Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC - Reuters